Sangamo and Lilly Partner on Capsid License for CNS Genomic Medicines
Sangamo Therapeutics, Inc. announced it has entered into a license agreement with Eli Lilly and Company (“Lilly”),…
Trending
- Sangamo and Lilly Partner on Capsid License for CNS Genomic Medicines
- Boehringer Ingelheim Expands ADC Portfolio with New R&D Center in Basel
- Neurona Therapeutics Raises $102M for NRTX-1001 Phase 3 Trial
- Rilzabrutinib Receives Orphan Drug Designation for Two Rare Diseases
- Novartis Gets FDA Accelerated Approval for Vanrafia in IgAN
- Flagship Pioneering and Pfizer Partner to Develop Selective Inhibitors for Autoimmune Diseases
- Astellas Partners with Japanese Cancer Foundation to Boost Oncology Research
- EU Approves Pfizer’s RSV Vaccine ABRYSVO for Adults 18-59
- Apellis Gets FDA Priority Review for EMPAVELI in C3G, IC-MPGN
- AIRNA Secures $155M in Oversubscribed Series B for Alpha-1 Antitrypsin Trial
Top Headlines
Boehringer Ingelheim Expands ADC Portfolio with New R&D Center in Basel
NBE Therapeutics (NBE) a wholly owned subsidiary of Boehringer Ingelheim, officially opened its new ADC R&D …
Neurona Therapeutics Raises $102M for NRTX-1001 Phase 3 Trial
Neurona Therapeutics, a clinical-stage, privately-held, biotherapeutics company developing regenerative cell…
Rilzabrutinib Receives Orphan Drug Designation for Two Rare Diseases
The US Food and Drug Administration (FDA) has granted orphan drug designation to rilzabrutinib, an investigational,…
Novartis Gets FDA Accelerated Approval for Vanrafia in IgAN
Novartis announced the US Food and Drug Administration (FDA) has granted accelerated approval for Vanrafia…
Flagship Pioneering and Pfizer Partner to Develop Selective Inhibitors for Autoimmune…
Flagship Pioneering announced an agreement between Pioneering Medicines, Flagship's in-house drug discovery and…
Featured Event
Clinical Trials
Neurona Therapeutics Raises $102M for NRTX-1001 Phase 3 Trial
Neurona Therapeutics, a clinical-stage, privately-held, biotherapeutics company developing regenerative cell therapies for disorders of the nervous…
Navidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024
Navidea Biopharmaceuticals, Inc. a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced…
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study
Neumora Therapeutics, Inc. announced that the Phase 1 trial of NMRA-266 has been placed on clinical hold by the U.S. Food and Drug Administration…
Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral nalbuphine ER) for the…
Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to…
Immunocore Holdings plc, a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically…
PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic…
PepGen Inc., a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the…
Fast shipping, security and absolute privacy is our main goal Viagra-Buy.com/ savings on their medication from a licensed and certified pharmacy.
The best pharmacy in america Viagra-Buy.com Fast delivery, best prices and for real men
Gensaic Partners with Novo Nordisk to Develop Next-Gen Precision Therapies
Gensaic, Inc. (Gensaic), a biotechnology company that combines AI-powered protein design with biological insights…
Merck Launches First Software for Complete Data Traceability in Microbial QC
Merck, a leading science and technology company, has launched its M-Trace Software & Mobile App, a…
Drug Research
AbbVie and Gubra Strike License Deal to Develop Amylin Analog for Obesity
AbbVie and Gubra A/S, a company specializing in preclinical contract research services and peptide-based drug…
Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop…
Biogen Inc. and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders…
AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License…
AbbVie and Gilgamesh Pharmaceuticals announced a collaboration and option-to-license agreement to develop…
AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific…
AbbVie Inc. and Tentarix Biotherapeutics announced a multi-year collaboration focused on the discovery and…
FDA Grants Orphan Drug Designation to NeoImmuneTech’s NT-I7 for the Treatment of…
NeoImmuneTech, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation…
Manufacturing
Charles River and Captain T Cell Announce Plasmid DNA and Viral Vector Manufacturing…
Charles River Laboratories International, Inc. and Captain T Cell, a spinoff from the renowned Max Delbrück Center…
Ribobay Pharma boosts CRDMO offerings with Cytiva’s first FlexFactory platform for…
Ribobay Pharma, a leading Chinese biopharmaceutical contract research, development, and manufacturing organization…
Micron Biomedical Receives $23.6 Million to Accelerate Commercial Manufacturing of…
Micron Biomedical, a life science company developing first-in-class dissolvable microarray-based products that…
Astraveus awarded €10.4 million grant by the French government as part of France 2030…
Astraveus SAS, the creator of modular, microfluidic cell foundries that transform cell and gene therapy (CGT)…
Samsung Biologics and Kurma Partners announce strategic partnership for development and…
Samsung Biologics and Kurma Partners announced a strategic partnership for the development and manufacturing of…
Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of…
Vaxcyte, Inc., a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind…
MilliporeSigma to Become First Provider to Offer Fully Integrated mRNA Services
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, is the first CTDMO…
Astellas to Invest more than €330 Million in a New State-of-the-Art Facility in Tralee,…
Astellas Pharma Inc. announced its intention to submit a planning application to build a new state-of-the-art…
Diseases
Apellis Gets FDA Priority Review for EMPAVELI in C3G, IC-MPGN
Apellis Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted and granted…
SK bioscience and Hilleman Laboratories Announce Joint Development of Second-Generation…
SK bioscience, an innovative vaccine and biotech company committed to promoting human health from prevention to…
Kesin Pharma Announces FDA Approval and U.S. Availability of LIKMEZ (metronidazole) Oral…
Kesin Pharma Corporation, a pharmaceutical company focused on innovative Specialty brands and Unit Dose…
Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss…
Regeneron Pharmaceuticals, Inc. and Decibel Therapeutics, Inc., a clinical-stage biotechnology company dedicated to…
Ionis enters collaboration to advance next generation program targeting Lp(a) for…
Ionis Pharmaceuticals, Inc. announced that it has entered a collaboration and license agreement with Novartis for…
FDA Approves Merck’s ERVEBO (Ebola Zaire Vaccine, Live) for Use in Children 12 Months of…
Merck, known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration…
